SCHEMBL7108630

SCHEMBL7108630

CC(C)C[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)c1ccccc1N)C(=O)N[C@@H](C)C(=O)NC(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 2/20 0.41
ALOX12 P18054 1/20 0.41
BACE1 P56817 2/20 0.41
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
HDAC1 Q13547 2/20 0.38
F2RL1 P55085 1/20 0.38
HDAC3 O15379 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
MAPT P10636 1/20 0.37
CLPP Q16740 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25382340 0.89 MMP8 (0.41) RAB9AALDH1A1OPRM1OPRD1OPRK1
SCHEMBL30565292 0.89 MMP8 (0.41) RAB9AALDH1A1OPRM1OPRD1OPRK1
SCHEMBL29456772 0.89 MMP8 (0.41) RAB9AALDH1A1OPRM1OPRD1OPRK1
SCHEMBL30482920 0.86 F2RL1 (0.41) RAB9AALDH1A1BACE1OPRM1OPRD1
SCHEMBL30482923 0.86 F2RL1 (0.41) RAB9AALDH1A1BACE1OPRM1OPRD1
SCHEMBL28861768 0.80 BACE1 (0.47) RAB9AALDH1A1BACE1OPRM1OPRD1
SCHEMBL11243260 0.79 PDF (0.43) RAB9AALDH1A1ALOX12BACE1SMN1; SMN2
SCHEMBL1393531 0.78 OPRD1 (0.36) RAB9ABACE1OPRM1OPRD1OPRK1
SCHEMBL9329807 0.77 BACE1 (0.49) RAB9ABACE1SMN1; SMN2NPC1TP53
SCHEMBL5680168 0.76 BACE1 (0.36) RAB9AALDH1A1ALOX12BACE1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170104-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2025-05-29 US disclosed
WO-2023166039-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-09-07 WO disclosed
EP-3475260-B1 COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR UNIV KONSTANZ (DE) 2022-03-30 EP disclosed
US-10961196-B2 Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor Universität Konstanz (DE) 2021-03-30 US disclosed
US-20190218183-A1 COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR Universität Konstanz (DE) 2019-07-18 US disclosed
EP-3475260-A1 COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR Universität Konstanz (DE) 2019-05-01 EP disclosed
WO-2017220205-A1 COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR Universität Konstanz (DE) 2017-12-28 WO disclosed
EP-3260445-A1 COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR Universität Konstanz (DE) 2017-12-27 EP disclosed
EP-1019434-B1 INHIBITORS OF METALLOPROTEINASES, THEIR THERAPEUTIC USE, AND PROCESS FOR THE PRODUCTION OF THE STARTING COMPOUND IN THEIR SYNTHESIS POLIFARMA SPA (IT) 2003-10-01 EP disclosed
US-6339160-B1 FOR THERAPY OF TUMORAL GROWTH AND METASTATIZATION, ATEROSCLEROSIS, MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, OSTEOPOROSIS, HYPERTENSION, RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY DISEASES POLIFARMA S.P.A. (IT) 2002-01-15 US disclosed
EP-1019434-A2 INHIBITORS OF METALLOPROTEINASES, THEIR THERAPEUTIC USE, AND PROCESS FOR THE PRODUCTION OF THE STARTING COMPOUND IN THEIR SYNTHESIS POLIFARMA S.p.A. (IT) 2000-07-19 EP disclosed
WO-1999003878-A2 INHIBITORS OF METALLOPROTEINASES, THEIR THERAPEUTIC USE, AND PROCESS FOR THE PRODUCTION OF THE STARTING COMPOUND IN THEIR SYNTHESIS POLIFARMA S.P.A. (IT) 1999-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218183-A1 COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR ZFR, ZC3HAV1, ZFX RAB9A 3657/4885ALDH1A1 4356/4885ALOX12 2714/4885
US-10961196-B2 Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor ZFR, ZC3HAV1, ZFX RAB9A 3657/4885ALDH1A1 4356/4885ALOX12 2714/4885
US-20250170104-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß LTA, SERPINB1, LAS1L RAB9A 1219/4885ALDH1A1 3061/4885ALOX12 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.